To date, the most frequently reported resistance mechanisms to second-line osimertinib, including analyses of circulating-tumor DNA (ctDNA) samples from patients in the Phase III AURA3 study are acquired EGFR mutations (e.g., C797S), and amplification of MET and ERBB2 (HER2)13–15. Here, ERBB2 is linked to neoplasm.